Inequalities in oncology care: Economic consequences of high cost drugs

M.G.H. Niezen, Elly A Stolk, Adri Steenhoek, Carin A Uyl-De Groot

Research output: Contribution to journalArticleScientificpeer-review

Abstract

The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Hospitals thus have to make impossible choices, so that eventually equal access can no longer be guaranteed. If no other policies are applied, health care goals will no longer be met. This paper tries to map the contours of the current problem and its possible solutions. It is time governments take up their responsibility and take back control.

Original languageEnglish
Pages (from-to)2887-92
Number of pages6
JournalEuropean Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC)
Volume42
Issue number17
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Drug Costs
Pharmaceutical Preparations
Delivery of Health Care

Keywords

  • Antineoplastic Agents
  • Budgets
  • Costs and Cost Analysis
  • Forecasting
  • Health Expenditures
  • Health Policy
  • Hospital Costs
  • Humans
  • Neoplasms
  • Socioeconomic Factors

Cite this

@article{c46be50c963b4bbcad4677508d543524,
title = "Inequalities in oncology care: Economic consequences of high cost drugs",
abstract = "The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Hospitals thus have to make impossible choices, so that eventually equal access can no longer be guaranteed. If no other policies are applied, health care goals will no longer be met. This paper tries to map the contours of the current problem and its possible solutions. It is time governments take up their responsibility and take back control.",
keywords = "Antineoplastic Agents, Budgets, Costs and Cost Analysis, Forecasting, Health Expenditures, Health Policy, Hospital Costs, Humans, Neoplasms, Socioeconomic Factors",
author = "M.G.H. Niezen and Stolk, {Elly A} and Adri Steenhoek and {Uyl-De Groot}, {Carin A}",
year = "2006",
month = "11",
doi = "10.1016/j.ejca.2006.07.009",
language = "English",
volume = "42",
pages = "2887--92",
journal = "European Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC)",
issn = "0959-8049",
publisher = "ELSEVIER SCI LTD",
number = "17",

}

Inequalities in oncology care : Economic consequences of high cost drugs. / Niezen, M.G.H.; Stolk, Elly A; Steenhoek, Adri; Uyl-De Groot, Carin A.

In: European Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC), Vol. 42, No. 17, 11.2006, p. 2887-92.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Inequalities in oncology care

T2 - Economic consequences of high cost drugs

AU - Niezen, M.G.H.

AU - Stolk, Elly A

AU - Steenhoek, Adri

AU - Uyl-De Groot, Carin A

PY - 2006/11

Y1 - 2006/11

N2 - The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Hospitals thus have to make impossible choices, so that eventually equal access can no longer be guaranteed. If no other policies are applied, health care goals will no longer be met. This paper tries to map the contours of the current problem and its possible solutions. It is time governments take up their responsibility and take back control.

AB - The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Hospitals thus have to make impossible choices, so that eventually equal access can no longer be guaranteed. If no other policies are applied, health care goals will no longer be met. This paper tries to map the contours of the current problem and its possible solutions. It is time governments take up their responsibility and take back control.

KW - Antineoplastic Agents

KW - Budgets

KW - Costs and Cost Analysis

KW - Forecasting

KW - Health Expenditures

KW - Health Policy

KW - Hospital Costs

KW - Humans

KW - Neoplasms

KW - Socioeconomic Factors

U2 - 10.1016/j.ejca.2006.07.009

DO - 10.1016/j.ejca.2006.07.009

M3 - Article

C2 - 16979891

VL - 42

SP - 2887

EP - 2892

JO - European Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC)

JF - European Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC)

SN - 0959-8049

IS - 17

ER -